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Abstract
Epstein-Barr virus (EBV) immortalizes resting B-cells and is a key etiologic agent in the development of numerous cancers.
The essential EBV-encoded protein EBNA 2 activates the viral C promoter (Cp) producing a message of ,120 kb that is
differentially spliced to encode all EBNAs required for immortalization. We have previously shown that EBNA 2-activated
transcription is dependent on the activity of the RNA polymerase II (pol II) C-terminal domain (CTD) kinase pTEFb (CDK9/
cyclin T1). We now demonstrate that Cp, in contrast to two shorter EBNA 2-activated viral genes (LMP 1 and 2A), displays
high levels of promoter-proximally stalled pol II despite being constitutively active. Consistent with pol II stalling, we detect
considerable pausing complex (NELF/DSIF) association with Cp. Significantly, we observe substantial Cp-specific pTEFb
recruitment that stimulates high-level pol II CTD serine 2 phosphorylation at distal regions (up to +75 kb), promoting
elongation. We reveal that Cp-specific pol II accumulation is directed by DNA sequences unfavourable for nucleosome
assembly that increase TBP access and pol II recruitment. Stalled pol II then maintains Cp nucleosome depletion. Our data
indicate that pTEFb is recruited to Cp by the bromodomain protein Brd4, with polymerase stalling facilitating stable
association of pTEFb. The Brd4 inhibitor JQ1 and the pTEFb inhibitors DRB and Flavopiridol significantly reduce Cp, but not
LMP1 transcript production indicating that Brd4 and pTEFb are required for Cp transcription. Taken together our data
indicate that pol II stalling at Cp promotes transcription of essential immortalizing genes during EBV infection by (i)
preventing promoter-proximal nucleosome assembly and ii) necessitating the recruitment of pTEFb thereby maintaining
serine 2 CTD phosphorylation at distal regions.
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Introduction
Epstein-Barr virus (EBV) is causally associated with the
development of numerous tumours including Burkitt’s lymphoma,
Hodgkin’s lymphoma, nasopharyngeal carcinoma and post-
transplant lymphoproliferative disease and immortalizes resting
B cells in vitro generating latently infected lymphoblastoid cell-lines
(LCLs) [1]. LCLs express 9 viral latent proteins: EBV Nuclear
Antigens (EBNAs 1, 2, 3A, 3B, 3C and LP) and three membrane
proteins (LMP 1, 2A and 2B). Following initial infection, EBNA-
LP and EBNA 2 are expressed from the viral W promoter (Wp).
EBNA 2 then drives promoter switching through activation of the
upstream viral C promoter (Cp) to produce a long message (up to
120 kb) that is differentially spliced to produce transcripts
encoding all nuclear antigens required for immortalization [2].
EBNA 2 also activates two promoters that direct transcription of
the EBV oncogene latent membrane protein 1 (LMP1) and the
viral LMP 2A and 2B genes [3–4]. EBNA 2 is directed to
promoters via association with the cellular DNA binding proteins
RBP-Jk and PU.1 [5–8]. Transcriptional activation by EBNA 2
involves the promotion of transcription initiation through
associations with histone acetyltransferases [9], chromatin remod-
elling complexes [10–11], and the basal transcriptional machinery
[12–14] and leads to Histone H3 and H4 acetylation at target gene
promoters in vivo [15]. The association of EBNA 2 with target
promoters is increased by asymmetric arginine dimethylation in
the arginine-glycine repeat region of the protein [16] and is
inhibited by phosphorylation on serine 243 during mitosis and
viral lytic cycle [17–19].
The carboxy-terminal domain (CTD) of RNA Polymerase II
(pol II) plays a central role in regulating efficient transcription
initiation, elongation and RNA processing. It contains 52
heptapeptide repeats (Y1S2P3T4S5P6S7) and is phosphorylated
largely on serines 2 and 5 during transcription [20]. Following pol
II recruitment, promoter-proximal serine 5 CTD phosphorylation
is mediated mainly by the TFIIH kinase, CDK7. Serine 2 CTD
phosphorylation catalysed by CDK9/Cyclin T1 (positive tran-
scription elongation factor b; p-TEFb) subsequently peaks at the 39
end of genes. Using the specific inhibitors 5,6-dichloro-1-b-D-
ribofuranosylbenzimidazole (DRB) and Flavopiridol, pTEFb has
been shown to be required for productive elongation [21–22] by
functioning as a CTD kinase and a regulator of the pol II-
associated complexes DRB sensitivity-inducing factor (DSIF) and
Negative Elongation Factor (NELF). DSIF and NELF induce
promoter-proximal pausing that is relieved following the phos-
phorylation of DSIF, NELF and the pol II CTD by pTEFb
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[23–26]. Although NELF is localized to promoters and promoter-
proximal regions in vivo, DSIF, in its phosphorylated form,
continues to associate with pol II throughout genes and functions
as a positive elongation factor capable of reducing polymerase
stalling at pause sites, preventing transcript release and stimulating
elongation [25,27]. Interestingly, although initial studies in
Drosophila documented the negative effects of NELF-induced
promoter-proximal pausing on transcription of a subset of genes,
including the Hsp70 locus [28–29], recent studies have demon-
strated that the presence of NELF is required for the efficient
transcription of the majority of Drosophila genes, forming a barrier
to nucleosome assembly around the promoter [30].
Although pTEFb activity may be required for the efficient
transcription of many cellular genes [22], not all gene transcription
is pTEFb-dependent [31–32] and it is clear that many cellular and
viral transactivators recruit and/or activate pTEFb to facilitate
high-level gene-specific transcription elongation [33]. The bromo-
domain protein Brd4 can also recruit pTEFb to promoters via
acetylated histones [34–35].
We have shown that EBNA 2 transcriptional activation requires
pTEFb activity and promotes serine 5 CTD phosphorylation [36].
In this study we investigated how long-range EBV transcription
required for viral immortalization is driven from the EBNA 2-
responsive C promoter. Our results provide the first demonstration
that significant levels of pol II accumulate specifically at Cp in
association with the pausing factors DSIF and NELF and that
pTEFb is recruited to the promoter at high level. Our data indicate
that promoter-proximal pol II accumulation at Cp is directed by
specific DNA sequences and maintains nucleosome depletion.
Pausing facilitates pTEFb recruitment via Brd4 to drive high-level
serine 2 CTD phosphorylation to promote production of the
EBNA-encoding transcripts required for EBV immortalization.
Results
EBNA 2 Stimulates CTD Phosphorylation on Serine 2 and
Serine 5 at Distal Genome Regions
We have previously demonstrated that EBNA 2 increases serine 5
CTD phosphorylation at viral latency promoter (Cp)-proximal and
downstream regions and requires pTEFb for activation of both Cp
and LMP1p [36]. To examine the role of EBNA 2 in facilitating
transcription of the very long primary transcript (,120 kb)
encoding all EBV nuclear antigens (EBNAs) from Cp, we probed
EBNA 2-driven changes in CTD phosphorylation at distal genome
regions. We examined Cp transcription in a pair of EBV-positive
Burkitt’s lymphoma (BL) clonal cell-lines that either maintain the
original EBNA 1-only (Latency I) BL tumour phenotype (Mutu I) or
have drifted in culture to express the full panel of latent antigens
including EBNA 2 (Mutu III) [37]. We found that EBNA 2 binding
to Cp peaked around the RBP-Jk site in Mutu III cells and was
undetectable in Mutu I cells as expected (Figure 1B). EBNA 2-
activated transcription in Mutu III cells resulted in increased serine
2 CTD phosphorylation which was evident from +295 and started
to increase significantly in the W repeat region of the genome
(typically 7.6 repeats located +666 to +24020 downstream fromCp),
remaining high up to approximately 60 kb downstream (Figure 1C).
In line with our previous observations in cells expressing
conditionally active EBNA 2 [36], we found that EBNA 2-activated
Cp transcription resulted in large increases in pol II recruitment and
serine 5 CTD phosphorylation at promoter-proximal regions
consistent with the promotion of transcription initiation (Figure 1D
and E). In this study we found that increased serine 5 CTD
phosphorylation was maintained at distal regions (Figure 1D). ChIP
assays using an antibody that precipitates total pol II detected
increases in the association of pol II with distal regions in Mutu III
cells compared to Mutu I cells (Figure 1E), consistent with the
promotion of transcriptional elongation by EBNA 2 to drive
synthesis of the full panel of EBNAs expressed in Mutu III cells.
Importantly, the observed changes in distal pol II CTD phosphor-
ylation could not be accounted for by increased pol II presence
alone, since increases in phospho-epitope levels exceeded the
increases in total pol II (Figure 1E). We confirmed that distal serine
2 CTD phosphorylation required functional EBNA 2 using cells
expressing a conditionally-active estrogen receptor-EBNA 2 fusion
protein [38]; high level serine 2 CTD phosphorylation was
detectable up to 75 kb downstream from Cp only in the presence
of beta-estradiol (Figure S1).
Interestingly, our experiments revealed a large peak of pol II
accumulation at Cp consistent with significant pol II stalling
despite the fact that Cp was constitutively active (Figure 1E). In
contrast, high levels of pol II were not detectable at the alternative
promoter Q (Qp, +38800 downstream from Cp) that drives EBNA
1 transcription in Mutu I cells (Figure 1A & E), despite the fact that
Q was fully active (Figure S2), indicating a lack of high-level pol II
recruitment or stalling at Qp.
pTEFb Is Recruited to Cp and Is Required for Distal Pol II
CTD Phosphorylation
We have previously demonstrated that EBNA 2-activated
transcription requires pTEFb activity [36]. Since CDK9 predom-
inantly phosphorylates the pol II CTD on serine 2 during
elongation through association with the travelling pol II complex
[39], we examined pTEFb recruitment at Cp. ChIP assays using
anti-CDK9 and anti-cyclin T1 antibodies demonstrated that high
levels of both subunits of pTEFb were associated with Cp in Mutu
III cells (Figure 2). Consistent with a role for pTEFb in distal serine 2
CTD phosphorylation, pTEFb was detectable in the W repeats and
at 31 kb downstream (Figure 2) but fell to levels below the limits of
detection of our ChIP assays thereafter. Previous studies have shown
that pTEFb levels can drop significantly and be barely detectable
using standard ChIP methods even 2 kb downstream from
promoters, despite clear evidence of pTEFb function (i.e. Serine 2
phosphorylation) at these regions [40–41]. To further confirm that
pTEFb was the kinase responsible for pol II CTD phosphorylation
beyond 31 kb,Mutu III cells were treated with the pTEFb inhibitor,
Author Summary
Epstein-Barr virus (EBV) is associated with the development
of a number of human cancers including Burkitt’s
lymphoma, Hodgkin’s lymphoma, nasopharyngeal carci-
noma and post-transplant lymphoproliferative disease. The
virus infects B cells rendering them immortal through the
production of a small number of viral proteins in the
latently infected cell. Many of the viral proteins required
for B-cell immortalization are produced from a very long
protein-coding RNA message that initiates at the main viral
latency promoter C, and our results provide important new
information on how this message is produced. Specifically
we show that the production of this long RNA is driven by
the recruitment of the elongation factor (pTEFb) to paused
transcription complexes at the C promoter. We show that
pTEFb is recruited by the chromatin-associated protein,
Brd4. Treatment of cells with a recently developed Brd4
inhibitor and inhibitors of the pTEFb elongation factor
inhibits production of transcripts derived from the long
EBV message thereby highlighting Brd4 and pTEFb
inhibitors as potential anti-EBV agents.
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DRB. Our results demonstrated that DRB ablated serine 2
phosphorylation on the pol II CTD and severely reduced
polymerase retention at distal regions (Figure 2). We also observed
a reduction in pol II phosphorylation on serine 5 at distal regions,
supporting previous observations of a role for pTEFb in catalysing
serine 5 phosphorylation during elongation (Figure S3) [39]. ChIP
Figure 1. High-level pol II accumulation at Cp and CTD phosphorylation at distal EBV genome regions. (A) Diagram showing the
locations of the amplicons generated by the indicated primer sets (Table S1) at the C promoter and around the circular EBV episome. Numbers
indicate the 59 end of the forward primer relative to the Cp transcription start site in the annotated B95-8 EBV sequence (NC_007605.1). The RBP-Jk
site (grey box) and TATA box (black box) are shown. (B) ChIP using anti-EBNA 2 antibodies. Percentage input signals, after subtraction of no antibody
controls, are expressed relative to the highest signal obtained in all or the majority of experiments. Results show the mean +/2 standard deviation of
a minimum of three independent experiments carried out using at least 2 chromatin batches from Mutu I cells (open bars) and Mutu III cells (black
bars). ChIP using anti-phospho serine 2 pol II CTD antibodies (C), anti-phospho serine 5 pol II CTD antibodies (D) and anti-pol II antibodies (E).
doi:10.1371/journal.ppat.1002334.g001
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for Tata box binding protein (TBP) confirmed that DRB treatment
did not have general non-specific effects on Cp pre-initiation
complex assembly (Figure S3). DRB treatment of cells expressing
conditionally active EBNA 2 also confirmed the requirement for
pTEFb for distal serine 2 CTD phosphorylation and pol II retention
up to 75 kb downstream during EBNA2-dependent transcription
(Figure S3).
High-levels of the Pausing Complexes NELF and DSIF Are
Present at Cp
To further investigate pol II stalling at Cp, we examined the
association of the pausing complexes NELF and DSIF with the
promoter. We detected high-levels of the NELF-A subunit of the
NELF complex and the Spt5 subunit of the DSIF Spt4-Spt5
heterodimer at Cp in Mutu III cells (Figure 3) consistent with DSIF
and NELF-induced polymerase stalling. Unlike NELF, which was
absent from distal regions of the template, Spt5 remained detectable
at distal regions consistent with a role for DSIF in promoting
transcriptional elongation [25,27] (Figure 3). EBNA 2-dependent
pausing complex recruitment to Cpwas confirmed in cells expressing
conditionally active EBNA 2 (Figure S4). Our results suggest that
recruitment of pTEFb to Cp is likely to be required to overcome
stalling induced by DSIF and NELF and promote elongation to
distal regions through serine 2 phosphorylation of the pol II CTD.
Low Level Pol II CTD Serine 2 Phosphorylation and
pTEFb, NELF and DSIF Recruitment at the EBNA 2-
regulated LMP Gene Locus
To determine whether polymerase stalling, high level pTEFb
recruitment and large increases in serine 2 CTD phosphorylation
were evident at other shorter EBNA 2-responsive transcription
units, we performed ChIP assays using primers specific for the
EBNA 2-activated LMP genes (Figure 4). Transcription of the
LMP2A gene is regulated by EBNA 2-via two RBP-Jk sites; EBNA
2-dependent LMP1 transcription is driven by a bidirectional
promoter located in the reverse orientation in the EBV genome via
EBNA 2 binding to both RBP-Jk and PU.1 (Figure 4A). This
bidirectional promoter also drives transcription of the LMP2B
gene. The LMP2A and LMP1 transcription units therefore
overlap and ChIP assays with primer sets 3–8 detect transcription
complexes associated with either or both genes (Figure 4A). ChIP
assays detected the same or higher levels of EBNA 2 binding to the
LMP1 and LMP2A promoters in Mutu III cells to those detected
at Cp (Figure 4B). Interestingly however, pTEFb recruitment to
LMP promoters was barely detectable and no pol II stalling was
evident at either LMP promoter (Figure 4). To rule out the
possibility that we had failed to detect a pol II peak at LMP2Ap
due to the location of our primer sets (2268 to 2185 and +150 to
+231), we designed an additional primer set spanning the
transcription start site (250 to +34). This primer set did not
detect any higher pol II signal than the flanking primer sets (Figure
S5). NELF and DSIF recruitment to the LMP locus was also
minimal (Figures 4 and S6). Consistently, pol II CTD serine 2
phosphorylation did not reach the high levels observed at distal Cp
regions and serine 5 phosphorylation on the pol II CTD was also
much reduced (Figure S6). Similar results were obtained when Cp
and the LMP locus were compared in an EBV-infected LCL
(Figure S7).
To exclude the possibility that low-level pol II and transcription
factor association with the LMP gene locus simply reflected low-
levels of LMP transcription in the cell-lines under study, we used
Figure 2. pTEFb is recruited to Cp and is required for serine 2 phosphorylation. Results show the mean +/2 standard deviation of a
minimum of three independent experiments carried out using at least 2 chromatin batches. Mutu I signals (open bars) are compared to Mutu III
signals (black bars) in ChIP using anti-CDK9 antibodies (A) or anti-cyclin T1 antibodies (B). (C) ChIP using anti-phospho serine 2 pol II CTD antibodies in
Mutu III cells minus (open bars) or plus 500 mM DRB (black bars). (D) ChIP using anti-pol II antibodies in Mutu III cells 2/+ DRB.
doi:10.1371/journal.ppat.1002334.g002
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real-time PCR to determine the levels of Cp-initiated EBNA 2 and
EBNA 1 transcripts and compared these to levels of LMP1
transcripts in Mutu III cells and two EBV-infected LCLs (Figure
S8). We found that LMP1 transcript levels were equivalent to the
levels of Cp-initiated EBNA 2 and EBNA 1 transcripts produced
in the same cell-line, although there were variations in the level of
transcripts produced between cell-lines probably as a result of
differences in EBV genome copy number (Figure S8).
Taken together, our data indicate that pol II accumulation and
high-level pTEFb recruitment is not a general characteristic of
EBNA2- activated promoters, but is specific to Cp. Moreover, the
level of promoter-associated pol II does not simply reflect the level
of gene transcription from Cp and LMP1p.
Pol II Stalling at Cp Maintains a Nucleosome-depleted
Region
Pol II stalling has recently been implicated in the promotion of
gene activity through the maintenance of a promoter-proximal
nucleosome-free region [30]. We therefore investigated whether
the region around Cp was depleted of nucleosomes in the presence
of stalled polymerase in Mutu III cells and an LCL where Cp is
active, compared to Mutu I cells where Cp is inactive. Nucleosome
levels were measured in ChIP assays using antibodies against the
core histone, histone H3 [41]. Strikingly, we detected an 84%
decrease in nucleosome occupancy at Cp in Mutu III cells
compared to Mutu I cells using primer sets that spanned the region
2208 to296 bp upstream of the transcription start site and a 78%
and 73% decrease with primer sets spanning regions +48 to +167
and 2430 to 2337, respectively (Figure 5). Nucleosomes were
similarly depleted from these regions in an EBV-infected LCL
(Figure 5). In contrast, levels of nucleosome depletion at similar
regions around LMP2Ap and LMP1p were much lower,
consistent with the absence of stalled pol II at these promoters
(Figure 5). It is therefore clear that in the absence of Cp activity in
Mutu I cells, nucleosomes assemble over promoter regions, but in
the presence of stalled polymerase in Mutu III cells, Cp is
maintained in a nucleosome-depleted state. In contrast, the low
levels of pol II initiating at the LMP promoters are unable to
maintain a highly nucleosome-depleted region and transient
remodelling is likely to facilitate initiation.
Pol II Stalling at Cp May Be Directed by Specific
Sequences that Allow Increased Access to the
Transcription Machinery
Gene-specificity of polymerase stalling may be directed by the
ability of promoters to recruit high levels of the general
transcription factor TFIID and thus high levels of polymerase
molecules [42–43]. Promoters that contain DNA sequences less
favourable for nucleosome assembly may therefore be predicted to
recruit TFIID and transcription complexes more efficiently and
accumulate stalled pol II in association with DSIF and NELF. To
test whether this could explain the specificity of polymerase stalling
at Cp, we examined the propensity of the DNA sequences around
Cp to assemble into nucleosomes using a nucleosome occupancy
prediction program http://genie.weizmann.ac.il/software/
nucleo_prediction.html [44]. This revealed a dramatic difference
in the probability of nucleosome occupancy at Cp compared to the
LMP promoters (Figure 6). The region of Cp encompassing the
Figure 3. DSIF and NELF are recruited to Cp in Mutu III cells. Results show the mean +/2 standard deviation of a minimum of three
independent experiments carried out using at least 2 chromatin batches. Mutu I signals (open bars) are compared to Mutu III signals (black bars). ChIP
using anti-Spt5 antibodies to detect DSIF (A) or anti-NELF-A antibodies to detect NELF (B). Blue-edged graphs show zoomed-in sections to allow
better visualization of downstream primer signals.
doi:10.1371/journal.ppat.1002334.g003
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TATA signal appears much less likely to be occupied by
nucleosomes compared to the equivalent regions of LMP1p and
LMP2Ap (TATA boxes are located at 231 to 226, 232 to 227
and 228 to 223 at the C, LMP1 and LMP2A promoters
respectively). Consistent with these predictions, ChIP assays using
an anti-TBP antibody detected dramatically lower levels of TBP
binding at the LMP promoters compared to Cp (Figure 6). We
detected high-level TBP association around the Cp TATA box
(2107 to 22) and upstream (2208 to 296) presumably as a result
of cross-linked interactions between TBP (TFIID) and the
transcription complex following initial TBP binding to the more
accessible TATA signal. Our data are therefore in agreement with
a model in which initial recruitment of high levels of pol II to Cp,
presumably in association with the pol II binding factors NELF
and DSIF, is driven by increased accessibility of the promoter to
TBP. It is clear however, that in the absence of active Cp
transcription in Mutu I cells, nucleosomes are able to assemble at
Cp (Figure 5) and that the reduced probability of nucleosome
occupancy may provide an initial advantage to pre-initiation
complex assembly, but does not completely preclude nucleosome
Figure 4. Pol II is not paused at the LMP gene loci and little pTEFb is recruited. (A) Diagram of the LMP gene locus showing the locations of
the amplicons generated by the indicated primer sets (1–8). Numbers indicate the 59 end of the forward primer relative to the starts of the LMP1 or
LMP2A mRNA sequences (bent arrows) in the B95-8 annotated EBV sequence (NC_007605). The RBP-Jk sites (grey boxes) and PU.1 site (black box) are
shown. The vertical arrow indicates the position of the LMP1 polyadenylation site. Results show the mean +/2 standard deviation of a minimum of
two independent experiments using Mutu I (open bars) and Mutu III cell chromatin (black bars). Percentage input signals, after subtraction of no
antibody controls, are expressed for comparison purposes relative to the highest signal obtained using Cp-specific primers. ChIP using anti-EBNA 2
antibodies (B), anti-CDK9 antibodies (C), anti-pol II antibodies (D) and anti-NELF-A antibodies (E).
doi:10.1371/journal.ppat.1002334.g004
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assembly. Moreover, the presence of stalled polymerase maintains
nucleosome depletion further upstream and downstream from the
Cp regions predicted to be less likely to be occupied by
nucleosomes since primer sets spanning 2430 to 2337 and
+295 to +406 detect reduced histone H3 levels (Figure 5).
Polymerase Stalling Stabilizes pTEFb Recruitment to Cp
Via Brd4
Although pTEFb can be recruited to promoters via association
with activators, we have been unable to demonstrate binding of
EBNA 2 to pTEFb (data not shown). To investigate the mechanism
of recruitment of pTEFb to Cp further, we examined the association
of the pTEFb binding protein, Brd4, with the promoter. Brd4 is
recruited via binding of its bromodomains to acetylated lysines in
Histones H3 and H4 [45]. We detected large increases in Histone
H3 and H4 lysine acetylation at Cp in Mutu III cells and
recruitment of the Histone acetyl transferase p300, previously
shown to interact with EBNA 2 [9] (Figure 7). Accordingly, Brd4
was recruited to Cp in Mutu III cells over a region spanning the
peaks of histone acetylation (Figure 7). We next examined whether
high-level Brd4 recruitment was Cp-specific. Our data demonstrat-
ed that Brd4 was also recruited to the LMP1 and LMP2A gene
promoters consistent with the peaks of Histone H3 and H4 lysine
acetylation and recruitment of p300 (Figure S9). Brd4 recruitment
per se could therefore not account for Cp-specific pTEFb
recruitment (Figures 2 and 4). Interestingly however, experiments
carried out in the presence of cellular stress revealed that pTEFb
recruitment to Cp correlates with Brd4 binding. In the presence of
cellular stress, such as that induced by exposure to Actinomycin D,
DRB or UV, pTEFb is released from an inactive pool, where it is
complexed with 7SK snRNA and the HEXIM1 protein, as part of a
stress response aimed at increasing transcription factor availability.
Released pTEFb then associates with Brd4 and the levels of the
pTEFb/Brd4 complex are increased [34,46–47]. DRB treatment
has been previously shown to result in a 2-fold increase in the level
of pTEFb/Brd4 complexes [34]. Consistent with these observa-
tions, we found that treatment of Mutu III cells with DRB resulted
in a two-fold increase in both Brd4 and pTEFb recruitment to Cp
indicating that Brd4 is responsible for recruiting pTEFb to Cp.
Histone H4 acetylation was increased by DRB treatment at Cp,
perhaps as a result of the protection from deacetylation provided by
the preferential binding of Brd4 to acetylated Histone H4 residues.
Previous studies have described inducible Brd4 recruitment via
acetylated histone H4 but not acetylated histone H3 residues [48]
and our data indicate that the pattern of Brd4 binding more closely
resembles the profile of histone H4 rather than histone H3
acetylation (Figures 7 and S9). In sharp contrast, DRB treatment
led to loss of Brd4 from the LMP1 promoter and decreases in
Histone H3 and H4 acetylation (Figure 8G-J) (pTEFb is not
detectably recruited to LMP1; Figure 4 and S5). Since the key
difference between the Cp and LMP1 promoters is the presence of
high levels of stalled pol II at Cp, these results suggest that pTEFb is
efficiently recruited to Cp via Brd4 as a result of stable interactions
between the pTEFb/Brd4 complex and the large numbers of stalled
Figure 5. Pol II pausing at Cp prevents nucleosome assembly
around the promoter. ChIP using anti-histone H3 antibodies. Results
show the mean +/2 standard deviation of a minimum of three
independent experiments carried out using at least 2 chromatin
batches in Mutu I cells (open bars), Mutu III cells (grey bars) and the PER
253 B95-8 LCL (black bars). Primer sets probed promoter-proximal
regions of Cp, LMP2Ap and LMP1p. Percentage input signals, after
subtraction of no antibody controls are expressed relative to the
highest signal obtained in all or the majority of experiments.
doi:10.1371/journal.ppat.1002334.g005
Figure 6. Pol II pausing at Cp is driven by DNA sequences that
promote access by TBP. (A) The probability of nucleosome
occupancy (P occupancy) at regions upstream and downstream from
the transcription start site (TSS) of Cp (thick black line), LMP1p (thick
grey line) and LMP 2Ap (thin black line) predicted using tools available
at http://genie.weizmann.ac.il/software/nucleo_prediction.html [44]. (B)
ChIP using anti-TBP antibodies analysed using Cp and LMP gene
primers (see Figure 4) in Mutu I cells (open bars) and Mutu III cells (black
bars). Results show the mean +/2 standard deviation of a minimum of
three independent experiments carried out using at least 2 chromatin
batches. Percentage input signals, after subtraction of no antibody
controls, are expressed for comparison purposes relative to the highest
signal obtained at Cp.
doi:10.1371/journal.ppat.1002334.g006
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polymerases present at the promoter. Thus at LMP1p, in the
absence of an accumulation of pol II molecules, pTEFb complexes
brought in by Brd4 have little polymerase with which to stably
associate and Brd4/pTEFb complex binding is not stabilized.
Interestingly, the essential EBV replication and transcription
factor EBNA 1 has been shown to recruit Brd4 to a region of the
latent origin of replication (OriP), that functions as an EBNA 1-
dependent Cp enhancer [49–50]. We therefore investigated the
possibility that EBNA 1 may recruit pTEFb to OriP via Brd4 and
contribute to the level of pTEFb at Cp through DNA looping
effects. Since EBNA 1 is expressed in Mutu I and Mutu III cells,
Brd4 would be expected to be recruited to OriP by EBNA 1 in
both cell types. ChIP analysis in Mutu I and Mutu III cells using
primers sets close to the family of repeats (FR) element in Ori P
where Brd4 was previously detected [49] revealed some Brd4
binding to Ori P in Mutu I and Mutu III cells, equivalent to that
detected in the GAPDH gene (Figure S10). The level of Brd4
detected was however much lower than that present at Cp and did
not appear to result in significant recruitment of pTEFb to this
region of the genome (Figure S10). Our data therefore indicate
that it is unlikely that pTEFb recruitment via Brd4 at OriP
contributes to the level of pTEFb at Cp.
We next sought to obtain direct evidence that Brd4 binding is
required for Cp but not LMP1 transcription by treatingMutu III cells
with the novel small molecule Brd4 bromodomain inhibitor, JQ1,
previously shown to block Brd4 association with acetylated histones
[51]. Strikingly, treatment with 50 nM JQ1 for 48 hrs reduced levels
of Cp-initiated EBNA 2 and EBNA 1 transcripts by 74% and 65%
respectively, but had no effect on LMP1 transcript levels (Figure 9A).
ChIP analysis confirmed that JQ1 dramatically inhibited Brd4
association with Cp promoter regions (Figure 9). The loss of Brd4
resulted in a significant decrease in pTEFb association with Cp,
consistent with Brd4-dependent recruitment of pTEFb to Cp
(Figure 9). In summary, our data indicate that the binding of Brd4
to Cp is required for Cp transcription since it facilitates the stable
association of pTEFb with the stalled polymerases present at Cp.
Inhibition of pTEFb Selectively Inhibits Cp Transcription
Since inhibition of Brd4 binding was sufficient to selectively
inhibit Cp transcription presumably through reduced pTEFb
recruitment, we investigated the effects of pTEFb inhibitors on
Cp and LMP transcription in Mutu III cells. We have previously
demonstrated that EBNA 2 activation of both Cp and LMP1
reporter constructs was inhibited by treatment with DRB or
overexpression of a dominant negative form of the pTEFb kinase,
CDK9 [36]. However, our current study indicates that LMP
promoters in vivo show little detectable pTEFb recruitment
(Figure 4). Consistent with the selective high-level recruitment of
pTEFb to Cp in vivo, we found that the pTEFb inhibitors DRB and
Flavopiridol were both able to inhibit Cp transcription at
concentrations at which LMP1 transcription was unaffected
(Figure 10). The discrepancy between our previous results and
these observations is likely explained by the fact that the promoter
context in transiently transfected reporter constructs differs
significantly from the appropriately assembled chromatin structures
found at promoters actively engaged in transcript production in
latently infected cells. Our data indicate that a reduced propensity
for nucleosome assembly around Cp allows high level recruitment of
TFIID and establishes polymerase pausing at the constitutively
active C promoter in infected cells. These Cp-specific features may
not have been established in transient assays. Thus pTEFb may be
important for EBNA 2-dependent Cp and LMP promoter activity
in reporter assay systems, but differences in pTEFb requirements
are evident in the context of latently infected cells.
Figure 7. Brd4 is recruited to Cp through acetylated histones. Results show the mean +/2 standard deviation of a minimum of three
independent experiments carried out using at least two chromatin batches from Mutu I cells (open bars) and Mutu III cells (black bars). ChIP using
anti-acetyl Histone H3 antibodies (A), anti-acetyl Histone H4 antibodies (B), anti-p300 antibodies (C) and anti-Brd4 antibodies (D).
doi:10.1371/journal.ppat.1002334.g007
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Discussion
EBV relies on the transcription of a long polycistronic mRNA to
encode the nuclear antigens (EBNAs) essential for immortaliza-
tion. Following initial production of EBNA-LP and EBNA-2 from
a cellular factor-driven promoter (Wp) after primary infection
[52–54], EBNA 2 activates an upstream promoter (Cp) leading to
long-range transcription and the full panel of EBNA expression
Figure 8. Brd4 recruits pTEFb to Cp. Results show the mean +/2 standard deviation of a minimum of three independent experiments carried out
using at least 2 chromatin batches from Mutu III cells in the absence (open bars) or presence of DRB (black bars). ChIP using anti-EBNA 2 (A and G),
anti-acetyl Histone H3 (B and H), anti-acetyl Histone H4 (C and I), anti-Brd 4 (D and J), anti-CDK9 (E) and anti-cyclin T1 antibodies (F). Cp analysis is
shown in A–F and LMP1p/LMP 2A analysis in shown in G–J.
doi:10.1371/journal.ppat.1002334.g008
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[2]. The molecular mechanisms behind this strategy have not been
fully elucidated. Our data show that the necessity for this promoter
switch goes beyond the simple advantage of utilizing a virally-
controlled promoter, and may reflect a requirement to promote
efficient transcriptional elongation ensuring production of the long
(approximately 120 kb) primary message. Our results indicate that
the specific recruitment of high levels of pTEFb to Cp in the
presence of EBNA 2 is required to promote distal transcriptional
elongation through serine 2 CTD phosphorylation and to
overcome promoter-proximal pol II stalling induced by the high
levels of the NELF/DSIF complex present at Cp. Our data suggest
that Cp-specific pol II stalling may play dual positive roles in
promoting transcription (i) by triggering the recruitment of pTEFb
and promoting distal elongation and (ii) by maintaining a
nucleosome-free region at the promoter that promotes initiation.
Our results document the presence of stalled RNA polymerase
at an actively transcribing viral gene locus, unlike the situation
observed at heat-shock genes, where genes temporarily in the
‘OFF’ state maintain promoter-proximally paused pol II to enable
a rapid transcriptional ‘ON’ response to heat-shock that results in
a re-distribution of polymerase along the gene [55]. Paused
polymerase does not remain detectable when Cp is ‘OFF’ in the
Mutu I cells used in this study because Cp is silenced in EBV
positive Latency I cells through CpG DNA methylation, thus
Figure 9. Brd4 is required for Cp transcription. (A) Transcription
of the Cp-initiated transcripts EBNA 2 and EBNA 1, but not the LMP1
transcript is inhibited when Brd4 binding to chromatin is blocked in the
presence of the Brd4 inhibitor JQ1. Mutu III cells were treated with
50 nM JQ1 or DMSO (control) for 48 hrs and transcript levels
determined using specific Q-PCR primers and actin as an endogenous
control. Normalised cDNA levels are expressed relative to 48 hr control
samples. ChIP using anti-Brd4 (B), anti-CDK9 (C) and anti-cyclin T1
antibodies (D) in Mutu III cells in the absence (black bars) or presence of
50 nM JQ1 for 48 hrs (open bars). Results show the mean +/2 standard
deviation of two independent experiments.
doi:10.1371/journal.ppat.1002334.g009
Figure 10. pTEFb inhibitors selectively reduce Cp transcription.
Mutu III cells were treated with the indicated concentrations of DRB (A)
or Flavopiridol (B) for 24 hrs and transcript levels determined using the
specific Q-PCR primers indicated and actin as an endogenous control.
Normalised cDNA levels are expressed relative to 24 hr control samples.
Results show the mean +/2 standard deviation of two independent
experiments.
doi:10.1371/journal.ppat.1002334.g010
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inhibiting transcription factor binding and pol II recruitment
[56–57]. Recent fine-mapping confirmed Cp methylation in Mutu
I cells and demonstrated a peak of 5-methyl cytosine close to Cp
that increased 7-fold in Mutu I cells compared to an LCL
generated from Mutu virus, where Cp is active [58].
Significantly, we demonstrate that regulation of Cp is distinct
from the regulation of the latent membrane protein promoters,
where only low levels of pol II, pTEFb, NELF and DSIF are
detectable and serine 2 CTD phosphorylation does not substan-
tially increase at distal regions. The EBNA 2-dependent LMP1,
LMP2A and 2B genes encode transcripts of 2.8 kb, 11.7 and
8.4 kb in length (in the B95-8 EBV genome sequence
NC_007605.1) so these shorter transcription units may therefore
be less dependent on elongation factor function. It is worth noting
that the LMP 2 transcription units can increase in size due the
presence of varying numbers of ,500 bp terminal repeat (TR)
elements that are present within these genes. On entry into host
cells, the EBV genome is initially in its linear form and the TR
region is the site of recombination-directed genome circulariza-
tion. Although the B95-8 genome sequence we have used for
transcript annotation contains 4 TRs spanning 2.1 kb, TR regions
of up to ,12 kb have been reported, indicating that LMP2A
transcripts can be up to 25 kb in length [59]. Nonetheless, the
,120 kb Cp transcription unit requires pol II to elongate over
considerably longer distances and our results indicate that it
possesses distinct regulatory features that promote long-range
transcription.
The specificity of pol II stalling at Cp appears to be driven by
the presence of DNA sequences upstream of Cp that are less
favourable for nucleosome assembly. These sequences encompass
the TATA box and therefore allow increased access to TBP
resulting in high-level recruitment of pol II in association with the
pausing factors NELF and DSIF. Once pol II stalling is established
at Cp, a more extensive region around the promoter is then
maintained in a nucleosome-depleted state. We have previously
demonstrated that pTEFb activity is required for the activation of
both Cp and LMP1 promoter-reporter constructs by EBNA 2
[36]. In the present study, the pTEFb components cyclin T1 and
CDK9 were virtually undetectable at either the LMP1/2B or
LMP2A promoters. In the context of latently infected EBV
immortalized cells we now show that endogenous Cp transcription
can be selectively inhibited by the pTEFb inhibitors DRB and
Flavopiridol at concentrations that do not affect LMP1 transcript
production. It is likely that chromatin structure in our previous
transient reporter constructs differs significantly from the chro-
matin context present in proliferating infected cells in vivo and thus
pausing factor and elongation factor requirements at Cp may not
have been faithfully recapitulated. The results presented in this
manuscript show that nucleosome occupancy is likely to be the
critical determinant that sets up Cp-specific polymerase pausing
and pTEFb recruitment on endogenous EBV templates. It would
be interesting to test whether Cp-specific regulatory features can
be conferred by Cp promoter sequences alone by generating
recombinant viruses in which LMP promoter regions are replaced
with Cp promoter regions.
Since the studies described here have exclusively examined the
nature of constitutive Cp transcription in established cell-lines, it
will be interesting to investigate the kinetics of the establishment of
polymerase stalling during primary B-cell immortalization, when
transcription switches from Wp to Cp approximately 6 days post-
infection [60], and the effects promoter switching has on CTD
phosphorylation and the elongation properties of pol II.
Interestingly, when we extended our nucleosome prediction
analysis to include Wp, we found that the region around the
Wp TATA box has a high probability of being occupied by
nucleosomes, similar to the results obtained for the LMP
promoters (Figure S11). Thus, based on our findings, Wp would
be less likely to accumulate stalled polymerases as a result of
increased TFIID access and pol II recruitment. The switch from
Wp to Cp usage may therefore be advantageous for the virus,
enabling high level pTEFb recruitment and increased efficiency of
elongation. It is interesting however, that Cp-deleted viruses
capable of transforming B-cells have been described and more
recently rare Burkitt’s lymphoma cells were identified that
exclusively use Wp to drive EBNA transcription [61–62]. These
observations suggest that Wp may be able to achieve sufficient
long-range transcription required for EBNA production during
immortalization in vitro or in certain cell backgrounds. Importantly,
the W promoter is present in multiple copies in the EBV genome
(e.g. 7.6 copies in the prototype Type 1 EBV strain, B95-8) and
transcription initiation from a number of W promoters may be
required to generate sufficient levels of downstream transcripts.
The fact that Cp deletion is a rare event however, supports the
notion that Cp plays a crucial role during EBV immortalization
and infected cell growth in vivo.
Since we detected the presence of Spt5 at distal regions, it is also
possible that the recruitment of DSIF may play a positive role in
Cp transcription, as documented for HIV transcription. pTEFb-
mediated phosphorylation of the Spt5 subunit of DSIF at
promoter-proximal regions converts DSIF into a positive-acting
elongation factor that travels with polymerase to promote
processivity and inhibit further pausing [25,27]. Spt5 has been
shown to promote transcriptional activation by Gal4-VP16 and is
recruited to the HIV-1 LTR to co-operate in the stimulation of
transcriptional elongation by HIV-1 Tat [25,63]. Further
experiments involving RNA interference would be useful in
dissecting the roles of DSIF in the regulation of Cp transcription.
EBV strains can be classified into two virus types (1 and 2,
formerly A and B) largely based on sequence differences between
the EBNA 2 genes, which share only 55% homology. Despite the
prevalence of type 2 viruses in Africa and their association with
BL, type 2 viruses transform resting B-cells much less efficiently
than type 1 strains and differences between the EBNA 2 genes
appear to be the major determinant of this property [64]. Recent
work has identified cellular genes that are differentially regulated
by type 1 and type 2 EBNA 2 indicating that reduced gene
activation by type 2 EBNA 2 may contribute to the reduced
transforming potential of type 2 viruses [65]. Since type 2 EBNA 2
also initially activates the LMP1 promoter to a reduced extent
[65], it is conceivable that differences in Cp control by type 1 and
type 2 EBNA 2 may also be evident. However, the results
described here indicate that high-level pTEFb recruitment to Cp is
driven by polymerase stalling initiated by DNA sequences that
promote reduced nucleosome occupancy around Cp, increasing
access to TFIID, rather than through specific properties of EBNA
2 (that may vary between strains). To investigate whether type 2
Cp sequences also possessed this property, we performed
nucleosome occupancy predictions using the sequence of the type
2 viral strain AG876. We found that nucleosome occupancy at the
type 2 C, LMP and W promoters was predicted to be virtually
indistinguishable (data not shown) from that of the type I B95-8
strain previously examined (Figure 6A and S11). This is perhaps
not surprising given the sequence similarity between the two
strains throughout most of the genome. Thus type 2 Cp sequences
show the same reduced likelihood of nucleosome occupancy as
type 1 viruses, compared to the respective LMP and W promoter
sequences, and would be just as likely to accumulate stalled
polymerases and recruit high-levels of pTEFb. It is therefore
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unlikely that pTEFb recruitment would contribute to the reduced
transforming potential of type 2 viruses, but further work is
necessary to address this point unequivocally.
Since we have been unable to detect an interaction between
EBNA 2 and pTEFb to date, we investigated alternative
mechanisms for the recruitment of pTEFb to Cp. The double
bromodomain protein, Brd4, has been shown to bind to the active
form of pTEFb and recruit it to promoters to stimulate elongation
[34–35]. Our data indicate that pol II stalling facilitates the
association of Brd4-recruited pTEFb with the C promoter by
providing high levels of pol II with which pTEFb can associate. In
support of this hypothesis the interaction of pTEFb with Brd4 has
been shown to be weak in nature and is disrupted by low salt
concentrations [34]. Thus despite similar levels of Brd4 binding to
Cp and the LMP gene loci, the lack of stalled pol II at LMP does
not facilitate stable pTEFb binding to the transcription complex.
Brd4 has been shown to play important roles in regulating viral
transcription and in tethering viral genomes to chromatin [66].
Brd4 enhances HIV-1 transcription and promotes transcriptional
activation of G1/S cyclin genes by murine gammaherpesvirus 68
(MHV-68) through direct interaction with MHV-68 orf73 [35,67].
Brd4 also plays an important role in the repression of human
papillomavirus transcription by the viral E2 protein and tethers
bovine and human papillomavirus genomes to mitotic chromo-
somes [68–69]. Brd4 was also recently shown to bind to the EBV
latent antigen EBNA-1 and to play a role in EBNA-1 activation of
transcription; knock-down or overexpression of Brd4 inhibited
EBNA-1 activated transcription in reporter assays [49]. It
therefore appears that Brd4 may play multiple roles in the EBV
life-cycle. Our data demonstrating specific inhibition of Cp-driven
EBV transcription by the novel Brd4 inhibitor JQ1 highlights the
potential for drug-like derivatives of this compound as anti-EBV
agents. In addition, our further evidence for the role of pTEFb in
promoting EBV transcription and the inhibition of Cp transcrip-
tion by pTEFb inhibitors adds weight to the possible use of the
pTEFb targeting anti-cancer drug, Flavopiridol, in the treatment
of EBV-associated tumours.
In summary, we demonstrate that polymerase stalling may play
a role in facilitating immortalization by the tumour virus EBV.
High-level recruitment of pol II and associated pausing factors to
the viral C promoter maintains nucleosome depletion and
necessitates pTEFb recruitment to overcome pausing. This
provides high levels of pTEFb to promote the distal serine 2
CTD phosphorylation required for production of the long viral
transcript encoding key EBV immortalizing genes.
Materials and Methods
Cell Culture
ER/EB 2.5 cells [38] were maintained as described previously
[36]. Mutu I (clone 179), Mutu III (clone 48), IB4 (provided by
Martin Rowe), PER 142 B95-8 LCL and PER 253 B95-8 LCL
(provided by Heather Long) were cultured as described [70]. For
Brd4/pTEFb inhibition experiments, Mutu cells were resus-
pended at 56105 cells/ml and incubated in the presence of
DMSO, JQ1/SGCBD01 [51] (kindly provided by Stefan Knapp,
Structural Genomics Consortium, University of Oxford), DRB
(Sigma) or Flavopiridol (Sigma) for 24 or 48 hours.
ChIP Assays
ER/EB 2.5 cells were washed and resuspended at 56105 cells/
ml in medium without b-estradiol. After 3 days 1 mM b-estradiol
(Sigma) was added for 5 hours and chromatin prepared as
described previously [36]. ER/EB 2.5 cells were treated with
100 mM DRB (or DMSO as a control) for 2 hrs as required prior
to addition of b-estradiol.
Mutu cells were diluted to 56105 cells/ml 24 hrs prior to
chromatin preparation and resuspended at 16107 cells/mL in
fresh media before crosslinking. Cells were treated with 500 mM
DRB for 2hrs prior to chromatin preparation.
ChIP methods were optimised for each target using a number of
alternative strategies.
For ER/EB 2.5 cells ChIP assays were carried out as described
previously [36] by overnight incubation at 4uC with 6 mg of
polyclonal antibodies (anti-Pol II; N-20, anti-Spt5; H-300, Santa
Cruz Biotechnology, Inc) followed by precipitation with protein A
sepharose beads pre-blocked with salmon sperm DNA. EBNA 2
immunoprecipitations were carried out using 8 mg of monoclonal
antibody (PE2) and an additional incubation with secondary
antibodies [36]. DNA was purified using the QIAquick Gel
extraction Kit (Qiagen) and eluted in 110 ml sterile millipore
water. Phospho serine 2 immunoprecipitations in ER/EB 2.5 cells
were carried out using a double-round ChIP protocol immuno-
precipitating first pol II and then the phospho-specific form.
Immune complexes from pol II precipitations were eluted and
diluted by addition of 850 ml IP dilution buffer. Second round
immunoprecipitations were carried out using protein sepharose A/
G beads (1:1 mix of protein A and G sepharose) preabsorbed first
with rabbit anti-mouse IgM immunoglobulins (20 mg) in 500 ml IP
dilution buffer overnight, and then with 25 mg anti-phospho ser 2
(H5) for 3–5 hours at 4uC. Prior to collection of immune
complexes, 100 ml of a 50% slurry of antibody pre-coated beads
were blocked using 350 mg salmon sperm DNA for 1 hr at 4uC.
Immune complexes were collected by rotation at 4uC overnight.
ChIP assays for EBNA 2 using Mutu cell chromatin were carried
out as for ER/EB 2.5 cells using 8 mg (PE2) antibodies. Pol II, Spt5,
acetylated Histone H3 and acetylated Histone H4 immunoprecip-
itations were carried out as described previously [36] by overnight
incubation of chromatin lysates with 5 mg of anti-pol II, anti-Spt5
(H-300), anti-CDK9 (H-169), anti-Cyclin T1 (H-245), anti-Brd4 (H-
250) (Santa Cruz Biotechnology, Inc), anti-acetyl-Histone H3 or H4
(Millipore) antibodies. ChIP assays for core Histone H3 were
carried out using 2 mg anti-Histone H3 antibody (Abcam, ab1791).
For NELF-A, immunoprecipitations were carried out using a
polyclonal antibody (Santa Cruz Biotechnology, Inc) and precoat-
ing protein A/G sepharose beads with 5 mg (anti-NELF-A; A20)
antibody overnight. Immune complexes were collected overnight
following blocking of pre-coated beads with salmon sperm DNA as
above. Phospho serine 2 and 5 immunoprecipitations using Mutu
cell chromatin were carried out in a single round ChIP by
precoating protein A/G sepharose beads with 10 mg rabbit anti-
mouse IgM overnight, prior to the addition of 25 mg H5 or 5 mg
H14 antibodies and then salmon sperm DNA as above. All controls
were treated identically but without addition of antibodies.
cDNA Preparation
Cells were diluted to 56105/ml, harvested after 24 hrs and total
RNA extracted using TriReagent (Sigma). RNA samples were
purified using the RNeasy kit (Qiagen) and cDNA was then
synthesised using the ImProm II reverse transcription system using
random oligonucleotides (Promega). For Brd 4 and pTEFb
inhibitor experiments, cDNA was prepared from 105 cells using
Power SYBR Green Cells-to-CT Kit (Applied Biosystems)
according to the manufacturer’s instructions.
PCR
Quantitative PCR (Q-PCR) was performed as described
previously [36] using an Applied Biosystems 7500 real-time
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PCR machine (95uC for 10 mins, 40 cycles at 95uC for 15 sec and
60uC for 1 min and dissociation curve analysis). For ChIP analysis,
an input control standard curve was generated for each primer set
(Table S1). Generally, cDNA samples were analysed using the
absolute quantitation method with standard curves generated from
Mutu I or Mutu III cDNA. Transcript levels were determined
using Qp or Cp-specific primers [71], cDNA-specific EBNA 2,
EBNA 1 (YUK) or LMP1-specific primers [72] and either the 18S
rRNA Quantitect primer assay (Qiagen) or actin primers as
normalization controls (Table S1). For Brd 4 inhibition experi-
ments, Q-PCR was carried out using Power SYBR Green Cells-to-
CT Kit (Applied Biosystems) and cDNA-specific EBNA 2, EBNA
1 (YUK) or LMP1-specific primers [72] with actin as the
endogenous control and analysed by Relative Quantification
(ddCt).
Immunoblotting
SDS-PAGE analysis and immunoblotting was carried out as
described previously [36,70]. Blots were probed with human M.S.
serum at 1/200 to detect EBNA 1 (gift from Martin Rowe), PE2 at
1/300 to detect EBNA 2 and anti-actin at 1/5000 (A-2066, Sigma).
HRP-conjugated anti-mouse (Dako) or anti-rabbit antibodies (Cell
Signalling Technology) were used to detect EBNA 2 and actin
respectively, and HRP-conjugated protein A (1/1000, Amersham
Biosciences) was used to detect EBNA 1 primary antibodies.
Accession Numbers
The type 1 EBV genome used for primer design, transcription
start sites and nucleosome predictions is the annotated sequence
from the B95-8 strain (NC_007605.1). The type 2 EBV genome
used was from the AG876 strain (NC_009334.1).
Supporting Information
Figure S1 Increased serine 2 phosphorylation on the pol
II CTD is dependent on EBNA 2 activity. (A) ChIP using
anti-EBNA 2 antibodies in ER/EB 2.5 cells cultured in the
absence (open bars) or presence of b-estradiol (black bars) shows
functional EBNA 2 binding only in the presence of b-estradiol (B)
ChIP using anti-phospho serine 2 pol II CTD antibodies detects
high-level serine 2 phosphorylation only in the presence of b-
estradiol. Results show the mean +/2 standard deviation of a
minimum of three independent experiments carried out using at
least 2 chromatin batches.
(PDF)
Figure S2 The Q promoter drives EBNA-1-only expres-
sion in Mutu I cells. (A) ChIP using anti-acetylated histone H3
antibodies and Mutu I (open bars) and Mutu III cell chromatin
(black bars). Results show the mean +/2 standard deviation of a
minimum of three independent experiments carried out using at
least 2 chromatin batches. Numbers indicate the 59 end of the
forward primer relative to the Cp transcription start site in the
annotated EBV sequence (NC_007605.1). Qp is located at +38800
relative to the Cp transcription start site. (B) PCR amplification of
Qp-specific and Cp-specific transcripts. Akata cells (Qp only) and
the PER 253 LCL (Cp only) served as positive controls for Qp and
Cp usage respectively. The IB4 LCL has a deletion upstream of
Cp so is negative for Qp and Cp transcripts. Qp or Cp signals
were normalised to 18S rRNA primer signals. (C) Western blot
analysis of whole cell lysates of Mutu I and Mutu III cells. Blots
were probed with M.S. human serum to detect EBNA 1, PE2 to
detect EBNA 2 and re-probed with anti-actin antibodies as a
loading control.
(PDF)
Figure S3 DRB treatment of Mutu III and ER/EB 2.5
cells inhibits CTD phosphorylation. (A) ChIP using anti-
phospho serine 5 pol II CTD antibodies in Mutu III cells minus
(open bars) or plus 500 mM DRB (black bars). (B) ChIP using anti-
TBP antibodies in Mutu III cells 2/+ DRB. (C) ChIP using anti-
phospho serine 2 pol II CTD antibodies in ER/EB 2.5 cells
cultured in the presence of b-estradiol and in the absence (open
bars) or presence (black bars) of 100 mM DRB. (D) ChIP using
anti-pol II antibodies in ER/EB 2.5 cells cultured in the presence
of b-estradiol and in the absence or presence of DRB.
(PDF)
Figure S4 Pausing factor recruitment is dependent on
the function of EBNA 2. ChIP using anti-Spt5 (DSIF)
antibodies in ER/EB 2.5 cells cultured in the absence (open bars)
or presence of b-estradiol (black bars) detects significant DSIF
recruitment only in the presence of functional EBNA 2.
(PDF)
Figure S5 Pol II is not paused at the LMP 2A promoter.
Results show the mean +/2 standard deviation of four
independent pol II ChIP experiments using Mutu I (open bars)
and Mutu III cell chromatin (black bars). Percentage input signals,
after subtraction of no antibody controls, are expressed for
comparison purposes relative to the highest signal obtained using
Cp-specific primers.
(PDF)
Figure S6 Low level pol II and elongation factor
recruitment at the LMP gene locus. (A) Primers across the
LMP locus are as in Figure 4. ChIP results show the mean +/2
standard deviation of a minimum of two independent experiments
using Mutu I (open bars) and Mutu III cell chromatin (black bars).
Percentage input signals, after subtraction of no antibody controls,
are expressed for comparison purposes relative to the highest
signal obtained using Cp-specific primers. (B) ChIP using anti-
phospho serine 2 pol II CTD antibodies. (C) ChIP using anti-
phospho serine 5 pol II CTD antibodies (D) ChIP using anti-cyclin
T1 antibodies. (E) ChIP using anti-Spt5 antibodies.
(PDF)
Figure S7 Low level pol II and elongation factor
recruitment at LMP genes in an LCL. ChIP carried out in
an EBV immortalised LCL (PER 253 B95-8 LCL). Primers across
the LMP locus are as in Figure 4. Results show the mean +/2
standard deviation of a minimum of three independent experi-
ments. Percentage input signals, after subtraction of no antibody
controls, are expressed for comparison purposes relative to the
highest signal obtained using Cp-specific primers. (A) ChIP using
anti-pol II antibodies. (B) ChIP using anti-Spt5 antibodies. (C)
ChIP using anti-NELF A antibodies.
(PDF)
Figure S8 Cp-initiated EBNA 2 and EBNA 1 transcript
levels are similar to those of LMP1. Transcript levels from
cDNA prepared at the same time from Mutu I, Mutu III, PER
253 B95.8 LCL and PER 142 B95.8 LCL were determined using
specific Q-PCR primers to EBNA 2, Cp-initiated EBNA 1 (YUK
spliced) and LMP1. Transcript quantities were determined using
the absolute quantitation method and a cDNA standard curve and
divided by actin quantities as a normalization control. Results
show mean +/2 standard deviation of Q-PCR duplicates from a
representative experiment. Note that EBNA 1 transcripts initiate
from Qp in Mutu I cells (Figure S2) and are not detected by the
YUK EBNA 1 primer set used here.
(PDF)
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Figure S9 Brd4 is recruited to LMP gene promoters.
Results show the mean +/2 standard deviation of a minimum of
three independent experiments using Mutu I (open bars) and
Mutu III cell chromatin (black bars). LMP gene locus primers are
as in Figure 4. Percentage input signals, after subtraction of no
antibody controls, are expressed for comparison purposes relative
to the highest signal obtained using Cp-specific primers. (A) ChIP
using anti-acetyl Histone H3 antibodies. (B) ChIP using anti-acetyl
Histone H4 antibodies. (C) ChIP using anti-p300 antibodies. (D)
ChIP using anti-Brd 4 antibodies.
(PDF)
Figure S10 pTEFb is not recruited to OriP at high levels.
Results show the mean percentage input signal (after subtraction of
the no antibody control signal) +/2 standard deviation of two
independent experiments using Mutu I (open bars) and Mutu III
cell chromatin (black bars). (A) ChIP using anti-Brd4 antibodies.
(B) ChIP using anti-CDK9 antibodies (C) ChIP using anti-cyclin
T1 antibodies. Cp analysis was carried out with the primer set that
gave the highest signal for each transcription factor. Ori P primers
are adjacent to the EBNA 1 binding element (family of repeats,
FR) (Table S1).
(PDF)
Figure S11 Nucleosome occupancy prediction analysis
at Wp resembles LMP genes. The probability of nucleosome
occupancy (P occupancy) at regions proximal to Cp, LMP1p,
LMP 2Ap and Wp was predicted using tools available at http://
genie.weizmann.ac.il/software/nucleo_prediction.html [44]. Cp,
LMP1p, LMP 2Ap and Wp TATA boxes are located at 231 to
226, 232 to 227, 228 to 223 and 231 to 226 relative to the
transcription start sites (+1).
(PDF)
Table S1 Real-time PCR primers. a Primer locations are
given relative to the start of the relevant mRNA sequence in the
annotated EBV sequence (NC_007605.1) or the GAPDH gene.
b Numbers relate to the annotated EBV sequence (NC_007605.1).
c Primers are located in the W repeat region which contains on
average 7.6 repeats of an estimated 3072bp sequence. d Primer
sequences obtained from Prof. Paul Lieberman, The Wistar
Institute, Philadelphia, USA. e Primer locations for the LMP1
gene located in the reverse orientation are given in parentheses.
f The LMP1 polyA is located at 166483 to 166488 so MW 361 is
outside of the transcription unit. g Actin primers span exon 3 to 4.
Nucleotide positions for chromosome 7 are shown (BC002409).
(PDF)
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